Normal total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) cannot completely exclude prostate cancer, and if prostate cancer is suspected, it is recommended to combine prostate MRI, rectal fingerprinting and other examinations to judge.
tPSA and fPSA tests have been widely used in clinical practice and become one of the important means for early diagnosis and screening of prostate cancer, and are the most specific indicators of prostate lesions. Elevated serum tPSA generally suggests the presence of lesions or damage to the prostate, including prostatitis, benign hyperplasia or cancer.
The positive rate of PSA in diagnosing prostate cancer is 80%, and the diagnostic specificity of prostate cancer can reach 90%-97% when the total serum prostate-specific antigen is ≥10 μg/L. However, if hormone therapy and other special conditions are carried out, it will affect the expression of prostate-specific antibodies, resulting in a decrease in the level of prostate-specific antigen, and therefore prostate cancer can not be completely excluded.
If there are symptoms such as difficulty in urination and blood in urine, it is recommended to improve the prostate MRI, rectal fingerprinting and other examinations to make a comprehensive judgment.